Start here: Approved treatments, experimental devices and future predictions are different categories. An intervention may have good evidence for one diagnosis and none for another. This guide is educational, not a treatment recommendation.
What could improve in the next 1, 5 and 10 years?
Next year · 2027
More results from wearable tic-device studies, accelerated TMS, newer ADHD and schizophrenia medicines, and late-stage depression trials. These are areas to watch, not guaranteed approvals.
Five years · 2031
Potentially better targeted stimulation and medication matching, with greater emphasis on daily-functioning outcomes and individual comorbidities. Large trials will decide which approaches persist.
Ten years · 2036
Adaptive brain-circuit therapies and molecular-subtype treatment may expand for selected groups; routine Neuralink-like psychiatric treatment is not established or predictable.
Research worth following
Each story has a plain-language explanation, an evidence label, an important safety consideration, and a primary research or regulator link.
New research explainer: What the November 10 FDA focused-ultrasound workshop does—and does not—mean for mental health care →
OCD · Depression · Cleared for specific indications
Deep TMS and accelerated TMS
Deep TMS has FDA-cleared protocols for OCD; several TMS approaches are cleared for depression. Accelerated schedules can reduce visits, but benefits depend on protocol and diagnosis. Not a general autism or Tourette treatment.
Important: History of psychosis, seizures or implanted devices deserves specialist assessment.
Source or research starting point ↗OCD · Depression · Psychiatric neurotechnology · Investigational for psychiatric uses; FDA workshop November 10, 2026
Transcranial focused ultrasound
A developing technology using targeted sound waves to study brain circuits. FDA and the Focused Ultrasound Foundation are discussing clinical-study design, safety monitoring and blood-brain barrier opening; the workshop is not an approval. Psychiatric outcome evidence is still limited.
Important: Do not confuse low-intensity neuromodulation with ablative ultrasound or other authorized ultrasound procedures. No general FDA psychiatric treatment claim is supported by the workshop.
Source or research starting point ↗Tourette syndrome · Promising research; check local medical-device status
Neupulse wrist stimulation
Median nerve stimulation from a wrist-worn device has shown tic-reduction signals in sham-controlled research. Access and medical regulatory status vary. A wellness device is not equivalent to an FDA-cleared tic treatment.
Important: Evidence for other co-occurring diagnoses is not established.
Source or research starting point ↗Schizophrenia · FDA approved October 9, 2026
WELTRUZA (monthly olanzapine)
A monthly subcutaneous long-acting injection for adults with schizophrenia. Phase 3 SOLARIS supported symptom and functioning benefit; it is a new delivery option for olanzapine, not proof of superiority to all other antipsychotics.
Important: Metabolic changes, weight gain, sedation and product-specific adverse effects require clinician monitoring.
Source or research starting point ↗Tourette syndrome · Promising Phase 3 evidence; investigational
Ecopipam (Tourette syndrome)
Randomized-withdrawal evidence supports maintenance of tic improvement in selected pediatric responders. October 2026 pooled and open-label analyses are encouraging but cannot establish long-term comparative effectiveness.
Important: Not FDA-approved; Priority Review targeted for late Q1 2027. CBIT remains established.
Source or research starting point ↗Treatment-resistant schizophrenia · Investigational; US FDA clinical hold
Evenamide
Newron disclosed four deaths in evenamide-treated study participants versus one in placebo and an unresolved potential arrhythmia signal. Causation is not established.
Important: Not approved. US trial enrollment remains on hold pending regulatory review.
Source or research starting point ↗PTSD and opioid-use disorder research · Experimental; FDA request for trial-design input
Ibogaine
An October 2026 FDA request seeks information about how early trials might safely investigate ibogaine in selected adults. Research planning does not establish clinical effectiveness or approval.
Important: Life-threatening arrhythmias related to QTc prolongation, potential neurotoxicity and drug interactions are serious known concerns.
Source or research starting point ↗Schizophrenia · FDA-approved in adults
Cobenfy (xanomeline/trospium)
A muscarinic-based schizophrenia medicine working differently from traditional dopamine-receptor antipsychotics. Benefits were demonstrated in adult trials, but this is not a treatment for autism, tics or OCD.
Important: Medication choice needs psychiatrist review of contraindications and monitoring.
Source or research starting point ↗ADHD · FDA-approved July 2026
Centanafadine (Simtriyo)
A new norepinephrine, dopamine and serotonin reuptake inhibitor option for ADHD. It is not approved specifically for rejection sensitive dysphoria or anxiety.
Important: Psychosis history, tics and interactions make individualized medication review essential.
Source or research starting point ↗Treatment-resistant depression · Investigational in the United States
Psilocybin-assisted treatment
Phase 3 trials have reported promising depression outcomes. Research findings are not yet proof of a safe, accessible treatment for multiple diagnoses.
Important: Particularly concerning in people with schizophrenia, mania or a history of psychosis.
Source or research starting point ↗Severe refractory OCD · Tourette research · Specialist / experimental applications
Adaptive deep brain stimulation
Implanted stimulation may eventually change its output based on recorded neural signals. DBS for severe OCD exists in restricted specialist pathways; adaptive psychiatric use is still developing.
Important: Surgery, infection, hardware and neuropsychiatric adverse effects need careful evaluation.
Source or research starting point ↗Neurotechnology · Early clinical research for paralysis
Neuralink and other brain-computer interfaces
BCIs can help some people with severe paralysis control computers and research systems have enabled speech synthesis. No demonstrated BCI treatment for autism, schizophrenia, OCD, ADHD, Tourette or anxiety currently exists.
Important: Restoring communication is not the same as modifying psychiatric circuits.
Source or research starting point ↗Autism-related genetic syndromes · Early trials
Genetic-subtype treatments
Gene-targeted research may someday support specific molecular syndromes such as Phelan-McDermid syndrome. Results cannot be generalized to autism as a whole.
Important: Genetic diagnosis and trial eligibility must be confirmed.
Source or research starting point ↗OCD · Tourette · Anxiety · Established treatments
ERP, CBIT and autism-adapted therapies
Exposure and response prevention is a central OCD treatment; comprehensive behavioral intervention for tics (CBIT) is an evidence-based tic treatment. Adaptations may improve accessibility for autistic people.
Important: Differentiate obsessions, delusions, tics, sensory distress and trauma before planning exposure.
Source or research starting point ↗Fatigue · Energy-limiting conditions · Self-management and tracking, not psychiatric treatment
Visible pacing app and wearable
Visible provides morning HR/HRV checks, symptom logs, optional wearable-based heart-rate zones and activity pacing. It is built for illnesses such as ME/CFS, long COVID and POTS. It might help people with overlapping fatigue or autonomic symptoms notice patterns, but has not been shown to treat autism, ADHD, OCD, Tourette, schizophrenia, depression or anxiety.
Important: Heart rate and HRV are nonspecific; alerts cannot reliably diagnose anxiety, agitation, psychosis or sensory overload. Some people may find monitoring stressful.
Source or research starting point ↗Could Visible help with these disorders?
Possibly with energy management and symptom observation, not as treatment of the disorders themselves. Visible is intended for pacing in energy-limiting conditions such as ME/CFS, long COVID and POTS. The free app offers daily check-ins and a health report; membership and a wearable add continuous heart-rate insights.
For autistic people or people with ADHD, depression or anxiety who also struggle with fatigue, sleep disruption or autonomic symptoms, structured tracking may make daily patterns easier to discuss with a clinician. There is no adequate evidence that Visible reduces delusions, OCD compulsions, tics, rejection sensitivity or core autism features. Its heart-rate/HRV metrics cannot determine why someone is distressed. Monitoring could increase anxiety for some users.
Visible: who it is designed for ↗ · Visible: free app features ↗
Considering treatment outside the United States?
Some countries have specialist research or restricted access pathways, but commercial availability is not evidence of effectiveness. Research Neupulse and UK studies, Australia’s tightly regulated psychedelic access, and European university trials through official registries. Avoid treating unapproved stem-cell, exosome or peptide programs as proven autism or psychiatric therapies.
FDA regenerative-medicine warning ↗
When several diagnoses overlap
Coordinate with the treating psychiatric team first. For active delusions, marked agitation, or worsening psychosis, prioritize timely psychiatric assessment before experimental neuromodulation, psychedelics or stimulant adjustments. Established ERP for OCD and CBIT for tics may be adapted after distinguishing obsessions from psychotic beliefs, sensory distress and trauma.
Updated October 2026; editorial information, not independently clinically reviewed. Trial phases, regulatory status and manufacturer reports can change. Verify indications, eligibility, risks and clinical outcomes with the original source and a qualified care team.